XL281: Interim Phase I data

In an ongoing, open-label, dose-escalation, U.S. Phase I trial in 29

Read the full 119 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE